千金药业：“地屈孕酮片”等产品取得注册证

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received drug registration certificates for three products from the National Medical Products Administration, indicating a significant regulatory approval milestone for the company [1] Group 2 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical, received approval for Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets [1] - The approval of these drugs may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [1]